查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1470383

尿道感染感染市場：按治療方法、最終用戶分類 - 全球預測 2024-2030

Urinary Tract Infection Market by Clinical Indication (Cystitis, Pyelonephritis, Urethritis), Treatment (Diagnosis, Therapatics), End User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

尿道感染市場規模預計 2023 年為 116.7 億美元，2024 年達到 124.7 億美元，預計 2030 年將達到 186.7 億美元，複合年成長率為 6.93%。

尿道感染，通常稱為 UTI，是指影響泌尿器官系統任何部位的細菌感染，包括腎臟、輸尿管、膀胱和尿道。大多數細菌感染疾病會影響下泌尿道，包括膀胱和尿道。由於其解剖結構，女性患尿道結石的風險高於男性。如果不及時治療，尿道結石會導致更嚴重的併發症，包括腎臟損傷。該市場包括抗生素治療、疼痛管理藥物、診斷測試（尿液培養和敏感性測試）、醫療設備（導尿管）和預防解決方案（預防尿道結石復發的抗生素）。由於社會老化以及糖尿病、腎結石等尿道結石高風險疾病的增加，迫切需要尿道結石的診斷和治療藥物。然而，診斷方法的敏感性和準確性有限以及多重抗藥性尿道結石細菌的日益流行引起了人們對尿道感染診斷方法和治療策略的可靠性和有效性的擔憂。然而，各大公司正在開發具有新作用機制的抗生素來對抗抗生素抗藥性。此外，透過快速、家庭或照護端檢測解決方案增強診斷也正在取得進展，以實現及時、準確的尿道結石檢測和管理。新興趨勢還包括採用遠端醫療諮詢和數位健康平台來管理和預防尿道結石。

主要市場統計
基準年[2023] 116.7億美元
預測年份 [2024] 124.7億美元
預測年份 [2030] 186.7億美元
複合年成長率（%） 6.93%

治療有臨床症狀的腎盂腎炎需要強大且先進的藥物策略

膀胱炎是膀胱的發炎，主要是細菌感染引起的。症狀包括尿急感、頻尿和排尿困難。治療通常涉及短期抗生素治療，但第一線藥物是首選，因為它們有效且促進抗生素抗藥性的風險較低。腎盂腎炎是尿道結石的一種更嚴重的形式，涉及腎組織感染。症狀更嚴重，包括發燒、腰部疼痛和噁心。治療通常需要使用更強的抗生素，最初可以靜脈注射。尿道炎是尿道的發炎，通常由細菌或病毒感染引起。症狀包括尿道分泌物和搔癢。治療方法取決於致病細菌；抗生素用於治療細菌感染，抗病毒藥物用於治療病毒感染。

最終用戶：隨著遠端醫療和電子醫療平台的普及，改善自我管理解決方案的最新進展

醫院是尿道結石治療市場的重要組成部分。醫院通常是需要即時就醫的嚴重和複雜尿道結石例的第一個接觸點。醫院需要採用診斷和治療方法的綜合方法來管理尿道結石。醫院提供的診斷服務包括尿液培養、敏感性測試和先進的分子診斷。治療通常涉及靜脈注射抗生素。自我管理治療針對的是喜歡在家治療的輕至中度尿道結石患者。由於店面銷售(OTC) 和電子醫療解決方案的便利性和可用性不斷提高，該行業正在經歷顯著成長。該部門包括電子健康解決方案和數位平台，透過遠端醫療和線上處方服務提供尿道結石管理。

區域洞察

以美國和加拿大為中心的美洲地區在研究、診斷開發和創新治療方面領先於尿道結石市場。尿道結石的高盛行率，加上強大的醫療基礎設施和患者意識，推動了對尿道結石的先進診斷和治療的需求。我們觀察到對專注於下一代抗生素和非抗生素方法的生物技術公司的大量投資。美國最近的專利包括新的診斷方法和先進的藥物傳輸系統，旨在改善患者的治療結果並降低復發率。由於不同的醫療政策和進入方式，歐盟國家呈現出不同的市場動態。然而，一個通用的趨勢是增加對抗菌素抗藥性研究和新治療方法開發的資助。歐盟對抗抗生素抗藥性感染疾病的承諾包括對針對尿道結石的研究和創新計劃進行大量投資。此外，遠端醫療和電子醫療服務的引入增加了患者接受尿道結石治療的機會。此外，與臨床診斷和治療設備的開發相關的嚴格法規的存在，為尿道結石診斷和治療解決方案的開發和進步創造了標準化的環境。亞太地區尿道結石市場的特徵是需求量大，對廉價治療方法的認知也不斷增強。政府的醫療保健舉措和蓬勃發展的學名藥行業正在推動成長。在日本、中國和印度等國家，許多研究都集中在治療尿道結石的草藥和替代藥物上，以回應消費者對非化學替代品的偏好。

FPNV定位矩陣

FPNV 定位矩陣對於評估尿道感染市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對尿道感染市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.尿道感染市場的市場規模與預測是多少？

2.在尿道感染市場預測期間內，有哪些產品、細分市場、應用和領域需要考慮投資？

3.尿道感染市場的技術趨勢和法規結構是什麼？

4.尿道感染市場主要供應商的市場佔有率為何？

5. 進入尿道感染市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 糖尿病和腎結石盛行率增加
      • 女性族群尿道感染率高
      • 過度使用抗生素和抗藥性增加導致複雜的尿道感染
    • 抑制因素
      • Aminoglycosides和Azole等治療藥物的副作用
    • 機會
      • 加強新型抗生素、疫苗和設備的研究和開發
      • 公眾意識和不斷上漲的醫療費用
    • 任務
      • 與尿道感染相關的社會恥辱
  • 市場區隔分析
    • 臨床適應症：需要強大且先進的藥物治療策略來治療腎盂腎炎
    • 最終用戶：隨著遠端醫療和電子健康平台的普及，在改進自我管理解決方案方面取得了最新進展
  • 市場趨勢分析
  • 俄羅斯-烏克蘭衝突的累積影響
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法規結構分析
  • 客戶客製化

第6章依臨床適應症分類的尿道感染感染市場

  • 膀胱炎
  • 腎盂腎炎
  • 尿道炎

第7章尿道感染感染治療市場

  • 診斷
  • 治療藥物

第8章尿道感染感染市場：依最終用戶分類

  • 醫院
  • 自我管理

第9章美洲尿道感染市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太尿道感染市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲尿道感染市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Vivoo 在 CES 2024 上推出家庭數位 UTI 測試
    • NRx Pharmaceuticals 宣布 FDA核准NRX-101 的臨床實驗申請 (IND)，NRX-101 是一種治療複雜尿道感染
    • 英恆與美國軍方合作開發治療尿道感染的噬菌體

第13章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-034B50030335

[187 Pages Report] The Urinary Tract Infection Market size was estimated at USD 11.67 billion in 2023 and expected to reach USD 12.47 billion in 2024, at a CAGR 6.93% to reach USD 18.67 billion by 2030.

A urinary tract infection, commonly termed a UTI, refers to a bacterial infection that affects any section of the urinary system, including the kidneys, ureters, bladder, and urethra. Most bacterial infections involve the lower urinary tract, which includes the bladder and the urethra. Women are at higher risk of developing a UTI than men due to their anatomy. If left untreated, a UTI can lead to more severe complications, including kidney damage. The market's scope encompasses antibiotic treatments, pain management medications, diagnostics tests (urine culture and sensitivity tests), medical devices (urinary catheters), and preventive solutions (prophylactic antibiotics for recurrent UTIs). A growth in the aging population and increasing incidences of conditions that are associated with a higher risk of developing UTIs, such as diabetes and kidney stones, has created an urgent need for UTI diagnostics and therapeutics. However, limitations with the sensitivity and accuracy of diagnostics procedures and the increasing prevalence of multi-drug resistant UTI pathogens raise concerns about the reliability and efficacy of urinary tract infection diagnostics and treatment strategies. However, key players are developing new antimicrobial agents with novel mechanisms of action to combat antibiotic resistance. Moreover, enhancing diagnostics with rapid, at-home, or point-of-care testing solutions to enable timely and accurate detection and management of UTIs is also gaining traction. Emerging trends also include the adoption of telemedicine consultations and digital health platforms aimed at UTI management and prevention.

KEY MARKET STATISTICS
Base Year [2023] USD 11.67 billion
Estimated Year [2024] USD 12.47 billion
Forecast Year [2030] USD 18.67 billion
CAGR (%) 6.93%

Clinical Indication: Need for potent and advanced medication strategies for the management of pyelonephritis

Cystitis represents inflammation of the bladder, predominantly due to bacterial infection. It manifests through symptoms such as urgency, frequency, and dysuria. Treatment usually involves a short course of antibiotics, with a preference for first-line agents considering their efficacy and low risk of promoting antibiotic resistance. A more severe form of UTI, pyelonephritis, involves infection of the kidney tissue. Symptoms are more intense, including fever, flank pain, and nausea. Treatment often necessitates the use of more potent antibiotics, potentially through intravenous (IV) routes initially. Urethritis involves inflammation of the urethra, typically caused by bacterial or viral infections. Presenting symptoms include urethral discharge and itching. The treatment depends on the causative agent, with antibiotics prescribed for bacterial infections and antivirals for viral causes.

End User: Recent advancements to improve self-administration solutions through the proliferation of telemedicine and e-health platforms

Hospitals represent a significant sector of the UTI treatment market. They are typically the first point of contact for severe and complicated UTI cases that require immediate medical attention. The need-based preference in hospitals includes a comprehensive approach to UTI management, utilizing both diagnostic and therapeutic modalities. Diagnostic services provided by hospitals include urine culture, susceptibility testing, and advanced molecular diagnostics. Treatment often involves the administration of intravenous antibiotics. Self-administered treatments cater to individuals with mild to moderate UTIs who prefer managing their condition at home. This sector has grown substantially, driven by the convenience and the increasing availability of over-the-counter (OTC) and e-health solutions. It can include e-health solutions and digital platforms offering UTI management through telemedicine and online prescription services.

Regional Insights

The Americas region, particularly the U.S. and Canada, leads in the UTI market in terms of research, diagnostic developments, and innovative treatments. The high prevalence of UTIs, coupled with strong healthcare infrastructure and patient awareness, drives the need for advanced diagnostics and therapeutic UTI procedures. Significant investments in biotechnology firms focusing on next-generation antibiotics and non-antibiotic approaches have been observed. Recent patents in the U.S. involve novel diagnostic methods and advanced drug delivery systems aimed at improving patient outcomes and reducing recurrence rates. EU countries exhibit diverse market dynamics due to varying healthcare policies and access. However, a common trend is the increasing research funding for antimicrobial resistance and the development of new treatment methods. The EU's commitment to combat antibiotic-resistant infections includes significant investment in research and innovation projects targeting UTIs. Moreover, the adoption of telemedicine and e-health services is enhancing patient accessibility to care for UTIs. Furthermore, the presence of stringent regulations pertaining to the development of clinical diagnostics and therapeutic devices has created a standardized landscape for the development and progress of UTI diagnostics and treatment solutions. APAC's UTI market is characterized by high demand for affordable treatments and increasing awareness. The growth is facilitated by government healthcare initiatives and a booming generic pharmaceuticals sector. Research in countries such as Japan, China, and India often focuses on herbal and alternative medicines for UTI treatment, catering to consumer preferences for non-chemical alternatives.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Urinary Tract Infection Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Urinary Tract Infection Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Urinary Tract Infection Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Almirall, S.A., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cipla Limited, Dr. Reddys Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Shionogi & Co., Ltd., Siemens Healthcare AG, Sun Pharmaceutical Industries Limited, Sysmex Corporation, Teva Pharmaceutical Industries Ltd., URIT Medical Electronic Co., Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Urinary Tract Infection Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Clinical Indication
    • Cystitis
    • Pyelonephritis
    • Urethritis
  • Treatment
    • Diagnosis
    • Therapatics
      • Aminoglycosides
      • Azoles
      • Quinolones
      • B-lactam
  • End User
    • Hospitals
    • Self-Administered
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Urinary Tract Infection Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Urinary Tract Infection Market?

3. What are the technology trends and regulatory frameworks in the Urinary Tract Infection Market?

4. What is the market share of the leading vendors in the Urinary Tract Infection Market?

5. Which modes and strategic moves are suitable for entering the Urinary Tract Infection Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing Prevalence of Diabetes and Kidney Stones
      • 5.1.1.2. High Incidences of UTI in Female Population
      • 5.1.1.3. Complicated UTI due to Rise in Excessive Use of Antibiotics and Drug-Resistance
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse Effects of Urinary Tract Infection Treatment Drugs such as Aminoglycosides and Azoles
    • 5.1.3. Opportunities
      • 5.1.3.1. Rise in R&D for a Novel Class of Antibiotics, Vaccines, and Devices
      • 5.1.3.2. Increase in Awareness among People and Healthcare Expenditure
    • 5.1.4. Challenges
      • 5.1.4.1. Social Stigma Concerning Urinary Tract Infections
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Clinical Indication: Need for potent and advanced medication strategies for the management of pyelonephritis
    • 5.2.2. End User: Recent advancements to improve self-administration solutions through the proliferation of telemedicine and e-health platforms
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis
  • 5.9. Client Customization

6. Urinary Tract Infection Market, by Clinical Indication

  • 6.1. Introduction
  • 6.2. Cystitis
  • 6.3. Pyelonephritis
  • 6.4. Urethritis

7. Urinary Tract Infection Market, by Treatment

  • 7.1. Introduction
  • 7.2. Diagnosis
  • 7.3. Therapatics

8. Urinary Tract Infection Market, by End User

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Self-Administered

9. Americas Urinary Tract Infection Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Urinary Tract Infection Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Urinary Tract Infection Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Vivoo launches at-home digital UTI test at CES 2024
    • 12.3.2. NRx Pharmaceuticals Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections
    • 12.3.3. Intron enters collaboration with the US Army on bacteriophages for urinary tract infections

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. URINARY TRACT INFECTION MARKET RESEARCH PROCESS
  • FIGURE 2. URINARY TRACT INFECTION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. URINARY TRACT INFECTION MARKET DYNAMICS
  • FIGURE 7. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. URINARY TRACT INFECTION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. URINARY TRACT INFECTION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. URINARY TRACT INFECTION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL URINARY TRACT INFECTION MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL URINARY TRACT INFECTION MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CYSTITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CYSTITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PYELONEPHRITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PYELONEPHRITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY URETHRITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY URETHRITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AZOLES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AZOLES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY QUINOLONES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY QUINOLONES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY B-LACTAM, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY B-LACTAM, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY SELF-ADMINISTERED, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY SELF-ADMINISTERED, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 38. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 39. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 40. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 47. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 48. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 49. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 50. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 51. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 52. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 53. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 54. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 55. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 56. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 57. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 58. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 59. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 60. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 61. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 62. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 63. CANADA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 64. CANADA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 65. CANADA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 66. CANADA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 67. CANADA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 68. CANADA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 69. CANADA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 70. CANADA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 71. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 72. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 73. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 74. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 75. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 76. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 77. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 78. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 79. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 80. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 81. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 82. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 83. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 84. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 100. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 102. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 104. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 106. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 107. CHINA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 108. CHINA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 109. CHINA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 110. CHINA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 111. CHINA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 112. CHINA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 113. CHINA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 114. CHINA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 115. INDIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 116. INDIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 117. INDIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 118. INDIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 119. INDIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 120. INDIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 121. INDIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 122. INDIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 123. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 124. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 125. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 126. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 127. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 128. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 129. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 130. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 131. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 132. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 133. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 134. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 135. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 136. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 137. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 138. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 139. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 140. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 141. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 142. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 143. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 144. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 145. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 146. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 148. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 150. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 152. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 154. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 155. SINGAPORE URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 156. SINGAPORE URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 157. SINGAPORE URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 158. SINGAPORE URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 159. SINGAPORE URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 160. SINGAPORE URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 161. SINGAPORE URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 162. SINGAPORE URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 164. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 166. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 168. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 171. TAIWAN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 172. TAIWAN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 173. TAIWAN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 174. TAIWAN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 175. TAIWAN URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 176. TAIWAN URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 177. TAIWAN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 178. TAIWAN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 179. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 180. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 181. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 182. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 183. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 184. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 185. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 186. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 187. VIETNAM URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 188. VIETNAM URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 189. VIETNAM URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 190. VIETNAM URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 191. VIETNAM URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 192. VIETNAM URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 193. VIETNAM URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 194. VIETNAM URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 205. DENMARK URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 206. DENMARK URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 207. DENMARK URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 208. DENMARK URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 209. DENMARK URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 210. DENMARK URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 211. DENMARK URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 212. DENMARK URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 213. EGYPT URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 214. EGYPT URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 215. EGYPT URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 216. EGYPT URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 217. EGYPT URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 218. EGYPT URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 219. EGYPT URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 220. EGYPT URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 221. FINLAND URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 222. FINLAND URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 223. FINLAND URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 224. FINLAND URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 225. FINLAND URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 226. FINLAND URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 227. FINLAND URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 228. FINLAND URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 229. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 230. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 231. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 232. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 233. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 234. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 235. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 236. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 237. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 238. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 239. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 240. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 241. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 242. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 243. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 244. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 245. ISRAEL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 246. ISRAEL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 247. ISRAEL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 248. ISRAEL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 249. ISRAEL URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 250. ISRAEL URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 251. ISRAEL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 252. ISRAEL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 253. ITALY URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 254. ITALY URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 255. ITALY URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 256. ITALY URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 257. ITALY URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 258. ITALY URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 259. ITALY URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 260. ITALY URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 262. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 264. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 266. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 268. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 269. NIGERIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 270. NIGERIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 271. NIGERIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 272. NIGERIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 273. NIGERIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 274. NIGERIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 275. NIGERIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 276. NIGERIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 277. NORWAY URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 278. NORWAY URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 279. NORWAY URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 280. NORWAY URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 281. NORWAY URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 282. NORWAY URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 283. NORWAY URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 284. NORWAY URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 285. POLAND URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 286. POLAND URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 287. POLAND URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 288. POLAND URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 289. POLAND URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 290. POLAND URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 291. POLAND URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 292. POLAND URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 293. QATAR URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 294. QATAR URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 295. QATAR URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 296. QATAR URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 297. QATAR URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 298. QATAR URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 299. QATAR URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 300. QATAR URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 301. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 302. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 303. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 304. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 305. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 306. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 307. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 308. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 310. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 312. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 314. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 316. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 317. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 318. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 320. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 322. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 324. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 325. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 326. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 327. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 328. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 329. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2023 (USD MILLION)
  • TABLE 330. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2024-2030 (USD MILLION)
  • TABLE 331. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 332. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 333. SWEDEN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2023 (USD MILLION)
  • TABLE 334. SWEDEN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2024-2030 (USD MILLION)
  • TABLE 335. SWEDEN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 336. SWEDEN URINARY